Pivotal Developmental Milestone Unveiled by MUSE Microscopy, Inc. at CAP24 Pathology Conference
MUSE Microscopy, Inc., has reached a pivotal developmental milestone, unveiling a preliminary version of its innovative SmartPath Imager at the recent CAP24 Pathology Conference in Las Vegas, NV. We introduced SmartPath as the first tissue-to-digital™ imager utilizing MUSE (Microscopy with Ultraviolet Surface Excitation) which we intend to create a solution that eliminates the need for traditional slide-based histology, a fundamental process that has remained unchanged for over a century.
Advanced Research in Digital Pathology
The eventual SmartPath Imager will be intended to represent an advance in pathology, reimagining the traditional workflow by directly capturing high-resolution, H&E-like digital images without invasive or destructive slide preparation. Utilizing a three-axis approach, we intend that our future SmartPath instrument generates comprehensive image volumes, offering depth and detail akin to layered histology.
Our goal is that SmartPath will illuminate tissue samples and digitize images, creating a rapid, standardized imaging process that advances the field of histology. By eliminating the labor-intensive slide preparation stage, such an instrument would potentially transform pathology labs from analog, slide-based processes to a seamless, tissue-to-digital workflow that could potentially preserve a tissue sample.
Designed to meet the demands of modern medicine, our team is researching ways to optimize workflow efficiency, image quality, and speed, addressing the critical requirements of today’s pathology professionals.
High Industry Interest at CAP24 Pathology Conference
The CAP24 conference highlighted an insightful product theater presentation on “Direct-to-Digital Instrumentation” by Dr. Jianyu Rao, Professor and Vice Chair of the Dept. of Pathology and Epidemiology, Vice Chair of Technology and Innovation, University of California, Los Angeles. MUSE Microscopy’s team was then invited to participate in a well-attended panel discussion, moderated by Dr. Aleksandra Zuraw of Digital Pathology Place, which explored the scientific and potential operational impact of SmartPath on pathology workflows.
Key insights shared by the panel, including remarks from distinguished experts such as Dr. Jianyu Rao, who has built among the largest international telepathology programs worldwide and Dr. Jeffrey Edwards, Sr. VP, Clinical Development, MUSE Microscopy, Inc., and former Global Head of Pathology at Antech Diagnostics, who oversaw the most significant digital pathology conversions worldwide. They highlighted SmartPath’s potential to enhance laboratory throughput, facilitate molecular imaging/quantification applications, and offer versatility in handling both fresh and wet-fixed tissue. This discussion underscored SmartPath’s team’s research goals which could eventually support a range of diagnostic and research applications. The Q&A session that followed allowed industry professionals to further engage with MUSE’s leadership, sparking ongoing dialogue and underscoring the value SmartPath team’s research can bring to pathology labs worldwide.
MUSE Microscopy’s Research Goals Hope to Redefine Digital Pathology at CAP24 and Beyond
We eventually hope to transform digital pathology through our SmartPath Imaging platform. As a tissue-to-digital solution, SmartPath is positioned to streamline tissue imaging and workflow integration. This potential innovation is designed to fill critical gaps in pathology.
With SmartPath’s potential advantages, our goal is to support rapid adoption across labs, healthcare institutions, and research centers. Our presence at CAP24 marked the start of a robust schedule, with our team committed to attending major industry events over the next year to strengthen network and drive engagement across global markets.
The statements made regarding the SmartPath Imager have not been evaluated by the Food and Drug Administration (FDA). The SmartPath System is currently intended for research use only. This medical device has not yet been evaluated, cleared or approved by the FDA. Its safety and effectiveness have not been established nor confirmed by FDA-approved research. SmartPath is not currently available for sale in the United States as a diagnostic aid or medical device for human pathology. This material is provided solely for informational purposes and does not substitute professional medical advice. It also does not constitute an offer to promote the device for any medical use.